Advertisement Pharmaceutical Business review - Page 2812 of 5285 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 10, 2026

Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs

Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku for its investigational topical drug ENERGI-F703DFU to treat diabetic foot ulcers (DFUs).

(From left to right) Tanabe Taiwan president Kakinoki Fumio, Energenesis Biomedical chairman Han-Min Chen, and Tanabe Pharma executive officer and Asia and Europe business division head Toshifumi Tada at the signing ceremony. Credit: Energenesis Biomedical / PRNewswire.